We are live on ! Find out more
BSPM

Biostar Pharmaceuticals, Inc.
BSPM

Delisted

BSPM was delisted on the 18th of September, 2018.

Back to rankings

7 hedge funds and large institutions have $330K invested in Biostar Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more capital invested

Capital invested by funds: $251K → $330K (+$79K)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

13% less funds holding

Funds holding: 8 → 7 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$145K
2
Morgan Stanley
Morgan Stanley
New York
+$91.5K
3
AIM
Acrospire Investment Management
Illinois
+$30.9K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$64K
2
CS
Credit Suisse
Switzerland
-$41K
3
UBS Group
UBS Group
Switzerland
-$13.9K
4
Barclays
Barclays
United Kingdom
-$1.19K

BSPM Hedge Fund Activity: Q4 2016 in Review

7 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Biostar Pharmaceuticals, Inc. (BSPM) for Q4 2016, worth a combined $330K — up 31% from $251K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of BSPM and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $145K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $64K sold.

  • 7 institutional investors held Biostar Pharmaceuticals, Inc. (BSPM) as of Q4 2016, down from 8 in Q3 2016.
  • Funds reported $330K of Biostar Pharmaceuticals, Inc. stock for Q4 2016, up 31% quarter-over-quarter.
  • 1 fund opened new Biostar Pharmaceuticals, Inc. positions in Q4 2016 and 2 closed out, a net change of -1 holder.
  • The largest Biostar Pharmaceuticals, Inc. buyer in Q4 2016 was JP Morgan Chase, an estimated $145K added.
  • The largest Biostar Pharmaceuticals, Inc. seller in Q4 2016 was Virtu KCG Holdings, an estimated $64K sold.

Based on aggregated 13F filings for Q4 2016.